MedKoo Cat#: 464573 | Name: BMV109

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BMV109 is a novel fluorescent activity-based probe (ABP), being intrinsically "dark" and only emitting fluorescence after reaction with the target protease, are ideally suited for imaging techniques such as small animal noninvasive fluorescence imaging and live cell fluorescence microscopy.

Chemical Structure

BMV109
CAS#1458731-58-2

Theoretical Analysis

MedKoo Cat#: 464573

Name: BMV109

CAS#: 1458731-58-2

Chemical Formula: C107H108F4N10O23S5

Exact Mass: 2136.6128

Molecular Weight: 2138.38

Elemental Analysis: C, 60.10; H, 5.09; F, 3.55; N, 6.55; O, 17.21; S, 7.50

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BMV109; BMV-109; BMV 109;
IUPAC/Chemical Name
1-((E)-9-(2-((4-((2-(4-(((S)-7-(6-((E)-2-((2E,4E)-5-(5-((l1-oxidaneyl)dioxo-l6-sulfaneyl)-1-ethyl-3,3-dimethyl-3H-indol-1-ium-2-yl)penta-2,4-dien-1-ylidene)-3,3-dimethyl-5-sulfoindolin-1-yl)hexanamido)-3-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-2-oxoheptyl)oxy)-2,3,5,6-tetrafluorobenzamido)ethyl)carbamoyl)piperidin-1-yl)sulfonyl)phenyl)-6-(5-sulfoindolin-1-yl)-3H-xanthen-3-ylidene)-1l4-indoline-5-sulfonate
InChi Key
KDFGXWUMTFTKSD-XYZCXLSZSA-N
InChi Code
InChI=1S/C107H108F4N10O23S5/c1-6-118-86-43-37-75(148(136,137)138)62-80(86)106(2,3)92(118)30-15-9-16-31-93-107(4,5)81-63-76(149(139,140)141)38-44-87(81)121(93)52-22-10-17-32-94(123)112-49-21-20-28-82(115-103(125)83(57-66-23-11-7-12-24-66)116-105(127)143-64-67-25-13-8-14-26-67)88(122)65-142-101-99(110)97(108)96(98(109)100(101)111)104(126)114-51-50-113-102(124)68-45-53-117(54-46-68)145(128,129)91-29-19-18-27-79(91)95-77-39-33-71(119-55-47-69-58-73(146(130,131)132)35-41-84(69)119)60-89(77)144-90-61-72(34-40-78(90)95)120-56-48-70-59-74(147(133,134)135)36-42-85(70)120/h7-9,11-16,18-19,23-27,29-31,33-44,58-63,68,82-83H,6,10,17,20-22,28,32,45-57,64-65H2,1-5H3,(H7-2,112,113,114,115,116,123,124,125,126,127,130,131,132,133,134,135,136,137,138,139,140,141)/t82-,83-/m0/s1
SMILES Code
O=S(C1=CC2=C(/[N+](CC2)=C3C=CC4=C(C5=CC=CC=C5S(=O)(N6CCC(C(NCCNC(C7=C(F)C(F)=C(OCC([C@@H](NC([C@@H](NC(OCC8=CC=CC=C8)=O)CC9=CC=CC=C9)=O)CCCCNC(CCCCCN%10/C(C(C)(C)C%11=C%10C=CC(S(=O)(O)=O)=C%11)=C/C=C/C=C/C%12=[N+](CC)C%13=C(C=C(S(=O)([O-])=O)C=C%13)C%12(C)C)=O)=O)C(F)=C7F)=O)=O)CC6)=O)C%14=C(C=C(N%15CCC%16=C%15C=CC(S(=O)(O)=O)=C%16)C=C%14)OC4=C\3)C=C1)([O-])=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 2,138.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Flanagan-Steet H, Christian C, Lu PN, Aarnio-Peterson M, Sanman L, Archer- Hartmann S, Azadi P, Bogyo M, Steet RA. TGF-ß Regulates Cathepsin Activation during Normal and Pathogenic Development. Cell Rep. 2018 Mar 13;22(11):2964-2977. doi: 10.1016/j.celrep.2018.02.066. PMID: 29539424; PMCID: PMC6247414. 2: Sensarn S, Zavaleta CL, Segal E, Rogalla S, Lee W, Gambhir SS, Bogyo M, Contag CH. A Clinical Wide-Field Fluorescence Endoscopic Device for Molecular Imaging Demonstrating Cathepsin Protease Activity in Colon Cancer. Mol Imaging Biol. 2016 Dec;18(6):820-829. doi: 10.1007/s11307-016-0956-7. PMID: 27154508; PMCID: PMC5564400. 3: Edgington-Mitchell LE, Bogyo M, Verdoes M. Live Cell Imaging and Profiling of Cysteine Cathepsin Activity Using a Quenched Activity-Based Probe. Methods Mol Biol. 2017;1491:145-159. doi: 10.1007/978-1-4939-6439-0_11. PMID: 27778287. 4: Withana NP, Saito T, Ma X, Garland M, Liu C, Kosuge H, Amsallem M, Verdoes M, Ofori LO, Fischbein M, Arakawa M, Cheng Z, McConnell MV, Bogyo M. Dual-Modality Activity-Based Probes as Molecular Imaging Agents for Vascular Inflammation. J Nucl Med. 2016 Oct;57(10):1583-1590. doi: 10.2967/jnumed.115.171553. Epub 2016 May 19. PMID: 27199363; PMCID: PMC5367444. 5: Ahmad H, Gupta V, Dwivedi AP, Katti SB, Dwivedi AK. Chiral Separation of Ormeloxifene Hydrochloride, a Non-steroidal Contraceptive Agent. J Chromatogr Sci. 2016 Feb;54(2):125-9. doi: 10.1093/chromsci/bmv109. Epub 2015 Aug 1. PMID: 26233489. 6: Segal E, Prestwood TR, van der Linden WA, Carmi Y, Bhattacharya N, Withana N, Verdoes M, Habtezion A, Engleman EG, Bogyo M. Detection of intestinal cancer by local, topical application of a quenched fluorescence probe for cysteine cathepsins. Chem Biol. 2015 Jan 22;22(1):148-58. doi: 10.1016/j.chembiol.2014.11.008. Epub 2015 Jan 8. PMID: 25579207; PMCID: PMC4353655.